HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability.

@article{Kim2014HBsAgSA,
  title={HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability.},
  author={Gi-Ae Kim and Young-Suk Lim and Jihyun An and Danbi J. Lee and Ju Hyun Shim and Kang Mo Kim and Han Chu Lee and Y H Chung and Yung Sang Lee and Dong Jin Suh},
  journal={Gut},
  year={2014},
  volume={63 8},
  pages={1325-32}
}
OBJECTIVE Little is known about the long-term clinical outcome and durability of HBsAg seroclearance following nucleos(t)ide analogue (NUC) therapy in patients with chronic hepatitis B (CHB). DESIGN During a median follow-up period of 6 years (33 567 patient-years) of 5409 CHB patients who were initially treated with lamivudine or entecavir, a total of 110 achieved HBsAg seroclearance (0.33% annual seroclearance rate) and were included in this study. RESULTS Baseline alanine… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
46 Citations
49 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 46 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 49 references

Restored function of HBVspeci fi c T cells after long - term effective therapy with nucleos ( t ) ide analogues

  • C Boni, A Penna, A Bertoletti
  • Gastroenterology
  • 2012

Similar Papers

Loading similar papers…